Advances in GLP-1 treatment: focus on oral semaglutide
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Background: There is currently a large arsenal of antidiabetic drugs available to treat type 2 diabetes (T2D). However, this is a serious chronic disease that affects millions of adults worldwide and is responsible for severe complications, comorbidities, and low quality of life when uncontrolled due mainly to delays in initiating treatment or inadequate therapy. This review article aims to clarify the therapeutic role of the oral formulation of the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide in treating typical T2D patients. The discussion focused on metabolic, glycemic, and weight alteration effects and the safety of the therapy with this drug. Main text: Therapy with glucagon-like peptide 1 receptor agonist (GLP-1 RA) promotes strategic changes in the pathophysiological pathway of T2D and improves the secretion of glucagon and insulin, which results in a reduction in blood glucose levels and the promotion of weight loss. Until recently, the only route for semaglutide administration was parenteral. However, an oral formulation of GLP-1 RA was recently developed and approved by the Brazilian Health Regulatory Agency (ANVISA) and the Food and Drug Administration (FDA) based on the Peptide Innovation for Early Diabetes Treatment (PIONEER) program results. A sequence of 10 clinical studies compared oral semaglutide with placebo or active standard-of-care medications (empagliflozin 25 mg, sitagliptin 100 mg, or liraglutide 1.8 mg) in different T2D populations. Conclusions: Oral semaglutide effectively reduces glycated hemoglobin (HbA1c) levels and body weight in a broad spectrum of patients with T2D and shows cardiovascular safety. Oral semaglutide broadens therapy options and facilitates the adoption of earlier GLP-1 RA treatment once T2D patients present low rates of treatment discontinuation. The main adverse events reported were related to the gastrointestinal tract, common to GLP-1 RA class drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most well-known mechanism through which GLP-1RAs affect weight loss is through the endocrine pathway, but its role in the nervous system should not be overlooked.415–417”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [417]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Controlling blood sugar is an extremely important practice to avoid or delay chronic diabetic complications [13].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“In the SUSTAIN-6 trial, the subcutaneous injection of semaglutide once a week reduced the relative risk of MACE by 26% compared to placebo [52].”
BackgroundSelf-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 3×
“2% of these patients had some form of CVD from 2007 to 2017 [11].”
BackgroundLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“The DIRECT trial demonstrates that a weight loss of approximately 15 kg can lead to T2D remission in approximately 80% of patients with obesity and T2D [8].”
BackgroundOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 13×
“PIONEER 6 assessed the CV outcomes of 14 mg of oral semaglutide in patients with T2D and high CV risk (defined as age ≥ 50 years with established CVD or CKD or age ≥ 60 years with CV risk factors only) [44].”
BackgroundMethodResultSelf-citationA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 5×
“Selected studies enrolled patients with recent acute coronary syndrome, stable cardiovascular disease, or cardiovascular risk factors [55].”
BackgroundInfluential
Research works printed but not linked: 2
- International Diabetes Federation. IDF Diabetes Atlas. 2019. 9th edition. https://www.diabetesatlas.org/en/. Accessed 15 Jan 2021.
- Blundell J, et al. Oral semaglutide reduces appetite and energy intake and improves control of eating in subjects with type 2 diabetes (Abstract #753). Barcelona: 55th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2019.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
“41 Guidelines for addressing side effects include improving eating habits, adapting food composition to personal requirements, increasing exercise, and keeping a food diary to identify trigger foods.”
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Self-citationOral Delivery of Therapeutic Antibodies with a Transmucosal Polymeric Carrier
Zhu, W., Chao, Y., Jin, Q., Chen, L., Shen, J., Zhu, J., Chai, Y., Lu, P., Yang, N., Chen, M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09266 · Cited by 57
Lipidization as a tool toward peptide therapeutics
Myšková, A., Sýkora, D., Kuneš, J., & Maletínská, L. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2284685 · Cited by 41
“Semaglutide is now available as an oral formulation and has been approved since 2019 by the FDA to treat t2DM (eliaschewitz & canani, 2021).”
Background
Metadata
- Authors
- Eliaschewitz, F. G., & Canani, L. H.
- Corresponding author
- Eliaschewitz, Freddy G.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2021-09-15
- Volume
- 13
- Issue
- 1
- Pages
- 99-99
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC8442336
- OpenAlex
- W3199150848
- Cited by
- 34
- References
- 64
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 7 · 2022: 5
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- novo nordisk farmacêutica do brasil ltda
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, GLP-1 receptor agonists, type 2 diabetes, glycemic control, HbA1c reduction, weight loss, cardiovascular safety, gastrointestinal adverse effects, empagliflozin, sitagliptin, liraglutide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in GLP-1 treatment: focus on oral semaglutide. https://app.cochat.ai/papers/10.1186/s13098-021-00713-9
- The paper
- Eliaschewitz, F. G., & Canani, L. H. (2021). Advances in GLP-1 treatment: focus on oral semaglutide. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-021-00713-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.